Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S0629: Tandem Transplant in WM
NCT00723658Phase 2Withdrawn
- Sponsor
- SWOG Cancer Research Network
- Start
- Sep 2008
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies, Modified Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, rituximab, thalidomide in Waldenstrom macroglobulinemia (WM), sponsored by SWOG Cancer Research Network. Planned start Sep 2008; status: withdrawn.
02
Drugs
bortezomibrituximabthalidomide
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT00723658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00723658.